Score Overview
Explore the 2021 public Archive ranking →
Where Eyepoint Pharmaceuticals Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- EYPT
2011: 24.1% · 2021: 88.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 3.42 | — |
1 Year2025-09-29 | $ 14.05 | -75.66% |
5 Years2021-09-29 | $ 10.28 | -66.73% |
10 Years2016-09-29 | $ 31.80 | -89.25% |
20 Years2006-09-29 | $ 96.00 | -96.44% |
All Time2005-01-27 | $ 401.60 | -99.15% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2005-01-27 |
|---|---|---|---|---|---|---|
| Price | $ 3.42 | $ 14.05 | $ 10.28 | $ 31.80 | $ 96.00 | $ 401.60 |
| Return | — | -75.66% | -66.73% | -89.25% | -96.44% | -99.15% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 2M | -$ 306M | $ 180M |
| 2025 | $ 31M | -$ 231M | $ 306M |
| 2024 | $ 43M | -$ 130M | $ 370M |
| 2023 | $ 46M | -$ 70M | $ 331M |
| 2022 | $ 41M | -$ 102M | $ 144M |
| 2021 | $ 36M | -$ 58M | $ 211M |
| 2020 | $ 34M | -$ 45M | $ 44M |
| 2019 | $ 20M | -$ 56M | $ 22M |
| 2018 | $ 2M | -$ 53M | $ 38M |
| 2017 | $ 7M | -$ 18M | $ 16M |
| 2016 | $ 1M | -$ 21M | $ 28M |
| 2015 | $ 26M | $ 6M | $ 28M |
| 2014 | $ 3M | -$ 13M | $ 18M |
| 2013 | $ 2M | -$ 11M | $ 10M |
| 2012 | $ 3M | -$ 24M | $ 14M |
| 2011 | $ 4M | -$ 8M | $ 24M |
| 2010 | $ 23M | $ 8M | $ 17M |
| 2009 | $ 12M | -$ 2M | $ 6M |
| 2008 | $ 3M | -$ 75M | $ 9M |
| 2007 | $ 2M | -$ 103M | $ 2M |
| 2006 | $ 1M | -$ 20M | $ 4M |
| IPO2005 | $ 629.52K | -$ 11M | $ 9M |
Eyepoint Pharmaceuticals Inc fundamental performance
Between 2015 and 2025, revenue grew from $ 26M to $ 31M and net income went from $ 6M to -$ 231M. Revenue increased in 6 of those 10 years; net income in 3.
Across Eyepoint Pharmaceuticals Inc's full reported history, from 2005 to 2025, revenue grew from $ 629.52K to $ 31M and net income went from -$ 11M to -$ 231M. Revenue increased in 62% of the years measured; net income in 38%.
Eyepoint Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.
Membership
Continue EYPT’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
